Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

GCV vs GRX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GRX Wins Head-to-Head Institutional Verdict (1–0 across 6 Pillars · 4–0 Matrix Metrics)

GRX Overall Winner 6-Pillar Tally: GCV 0 – 1 GRX (5 Tie) Matrix Metrics: GCV 0 – 4 GRX

As of Nov 16, 2026, The Gabelli Healthcare & Wellness Trust (GRX) is the stronger overall head-to-head candidate over The Gabelli Convertible and Income Securities Fund, Inc. (GCV) in the Tradestie Institutional Equity Comparison Engine, winning 4–0 core matrix metrics and 1–0 across our 6-pillar institutional scorecard (led by Growth & Scale). GCV carries a Unified Composite Score of 36.3/100 (SELL) at $3.71 (N/M Forward P/E, N/A operating margin), whereas GRX carries 44.3/100 (HOLD) at $10.58 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: GCV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.3); meanwhile GRX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GCV vs GRX
GCV NYSE
The Gabelli Convertible and Income Securities Fund, Inc.
Institutional Equity
$3.71
-2.62% 1D
Market Cap $83.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.80β · 21% Vol
Unified Composite Score
36.3 / 100 SELL
Tech 8.0 Fund 57.0 Flow 50.0 Mom 73.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.8%), weak momentum, RSI 29
RSI-14: 29.3 · SMA20: $3.87 · SMA50: $4.10
GRX NYSE Head-to-Head Winner
The Gabelli Healthcare & Wellness Trust
Institutional Equity
$10.58
+1.63% 1D
Market Cap $142.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.14β · 14% Vol
Unified Composite Score
44.3 / 100 HOLD
Tech 29.0 Fund 44.0 Flow 50.0 Mom 56.2
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.9% over 20 days), RSI 67
RSI-14: 67.1 · SMA20: $10.24 · SMA50: $9.90

6-Pillar Scorecard Institutional Category Breakdown (GCV 0 – 1 GRX)

Columns: Metric · GCV · GRX
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale GRX
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap $83.5M $142.9M
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GCV (0) vs GRX (4)
Institutional Metric GCV GRX Criterion Row Edge
Market Capitalization
Scale
$83.5M $142.9M Larger Scale GRX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
16% ($4–$5) 91% ($9–$11) Stronger Trend GRX
Beta / 30D Volatility
Risk Regime
0.80β · 21% Vol 0.14β · 14% Vol Lower Realized Risk GRX
Unified Institutional Score
Composite Signal
36.3 / 100 (SELL) 44.3 / 100 (HOLD) Higher Composite GRX
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GRX +11.41 pp
GCV: -6.55% · GRX: +4.86%
3M Horizon GRX +26.35 pp
GCV: -19.7% · GRX: +6.65%
6M Horizon GRX +36.53 pp
GCV: -17.92% · GRX: +18.61%
1Y Horizon GRX +21.88 pp
GCV: -10.39% · GRX: +11.49%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GCV vs GRX. Trailing 12-month operating profitability (GCV N/A vs GRX N/A) and valuation multiples (GCV N/M vs GRX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

GCV ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
GRX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GCV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GCV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GRX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GCV Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with $83.5M market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
GRX Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with $142.9M market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ GCV vs GRX Key Questions & Quantitative Answers

As of Nov 16, 2026, The Gabelli Healthcare & Wellness Trust (GRX) is the stronger overall head-to-head candidate over The Gabelli Convertible and Income Securities Fund, Inc. (GCV) in the Tradestie Institutional Equity Comparison Engine, winning 4–0 core matrix metrics and 1–0 across our 6-pillar institutional scorecard (led by Growth & Scale). GCV carries a Unified Composite Score of 36.3/100 (SELL) at $3.71 (N/M Forward P/E, N/A operating margin), whereas GRX carries 44.3/100 (HOLD) at $10.58 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: GCV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.3); meanwhile GRX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

GRX leads the Growth & Scale pillar: GCV posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with GRX at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, GCV generates N/A in USD-normalized revenue versus N/A for GRX. In operating R&D and SG&A reinvestment, GCV deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GRX.

GCV and GRX trade at balanced relative valuation multiples. GCV trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas GRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GCV (N/A ROE) versus GRX (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, GCV carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.80β · 21% Vol realized risk). By comparison, GRX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 14% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

The Gabelli Convertible and Income Securities Fund, Inc. (GCV) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.